23andMe, founded in April 2006 by Linda Avey, Paul Cusenza, and Anne Wojcicki. The company has not officially endorsed a plan to participate in an IPO.

23andMe provides at-home, consumer genetic testing and was the first FDA-approved direct-to-consumer genetic sequencing supplier. More recently, 23andMe has leveraged its genetic database in pursuit of pharmaceutical drug development. The company has raised nearly $800 million in Venture Capital funding from investors including GlaxoSmithKline, Pegasus Tech Ventures, MicroVentures, G Squared, Sapphire Ventures, Sequoia Capital, SharesPost, Fidelity, GV, and Genetech. It has been widely reported that 23andMe last raised $300 million in July 2018 at a post-money valuation of $2.5 billion.

Register for Details

For more details on financing and valuation of private companies similar to 23andMe before its , register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn More About 23andMe

To invest in 23andMe pre-IPO

Can you invest in 23andMe pre-IPO?

You may invest in 23andMe as it is a public company listed on the NASDAQ with ticker ME. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of 23andMe before it goes public?

You can no longer sell shares of 23andMe on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my 23andMe shares?

Forge can no longer determine the value of 23andMe shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is 23andMe a publicly traded company?

23andMe became a public company following its SPAC on 06/17/2021 and is now traded on the NASDAQ under the ticker ME.

To learn more about 23andMe potential IPO

Will 23andMe go IPO?

23andMe became a public company following its SPAC on 06/17/2021 and is now traded on the NASDAQ under the ticker ME.

What is 23andMe’s IPO price?

The IPO price of 23andMe is not currently available.

When was 23andMe founded?

23andMe was founded in 2006.

What is 23andMe funding to date?

23andMe has raised $876.61MM to date.

Who are 23andMe’s major investors?

Casdin Capital
Glaxosmithkline
Mpm Capital
Fidelity Management
Fidelity Investments
Altimeter Capital
Roche Venture Fund
Xfund
Other Individual Investors
Illumina
Newview Capital
Wallenberg Foundation
Sequoia Capital
Mohr Davidow Ventures
Google
New Enterprise Associates
Wuxi Venture Fund
Genentech
Google Ventures
Johnson & Johnson
Euclidean Capital

23andMe Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
12/23/2020 Series F-1 $385MM $xx.xx $2.59B Glaxosmithkline, Newview Capital, Sequoia Capital
Price per Share
$xx.xx
Shares Outstanding
22,190,201
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Glaxosmithkline, Newview Capital, Sequoia Capital
09/12/2017 Series F $250MM $xx.xx $1.75B Altimeter Capital, Casdin Capital, Euclidean Capital, Fidelity Management, Sequoia Capital, Wallenberg Foundation
Price per Share
$xx.xx
Shares Outstanding
18,006,075
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Altimeter Capital, Casdin Capital, Euclidean Capital, Fidelity Management, Sequoia Capital, Wallenberg Foundation
06/08/2015 Series E $115.25MM $xx.xx $1.1B Casdin Capital, Fidelity Management, Google Ventures, Illumina, Mpm Capital, New Enterprise Associates, Wuxi Venture Fund, Xfund
Price per Share
$xx.xx
Shares Outstanding
10,644,057
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Casdin Capital, Fidelity Management, Google Ventures, Illumina, Mpm Capital, New Enterprise Associates, Wuxi Venture Fund, Xfund
12/10/2012 Series D $58.45MM $xx.xx $288.74MM Google Ventures, Mpm Capital, New Enterprise Associates, Other Individual Investors
Price per Share
$xx.xx
Shares Outstanding
14,435,636
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Google Ventures, Mpm Capital, New Enterprise Associates, Other Individual Investors
11/10/2010 Series C $31.18MM $xx.xx $184.5MM Google Ventures, Johnson & Johnson, Mpm Capital, New Enterprise Associates, Roche Venture Fund
Price per Share
$xx.xx
Shares Outstanding
9,898,011
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Google Ventures, Johnson & Johnson, Mpm Capital, New Enterprise Associates, Roche Venture Fund
12/23/2009 Series B $27.78MM $xx.xx $150.5MM Google, New Enterprise Associates, Other Individual Investors
Price per Share
$xx.xx
Shares Outstanding
9,048,560
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Google, New Enterprise Associates, Other Individual Investors
05/22/2007 Series A $8.95MM $xx.xx $48.5MM Genentech, Google Ventures, Mohr Davidow Ventures, New Enterprise Associates
Price per Share
$xx.xx
Shares Outstanding
7,119,936
Liquidation Pref Order
6
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Genentech, Google Ventures, Mohr Davidow Ventures, New Enterprise Associates
Updated on: Dec 22, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.